ICON Public Company (ICLR) Leerink’s Global Healthcare Conference 2025 summary

Market dynamics and industry outlook

• Pharma customers face major revenue loss from loss of exclusivity, requiring $200B in new revenue over five years to maintain growth.

• Budget cuts and portfolio rationalizations are ongoing, but long-term outsourcing demand is expected to rise.

• Biotech sector remains volatile, with many companies under cash value, but some positive signs are emerging.

• Some large customers are stabilizing, while others remain in flux; new strategic partners are entering the top five.

• Portfolio impact is mixed, with some customers declining and others growing, especially in oncology and rare diseases.

Strategic partnerships and customer trends

• Recent strategic wins include customers shifting from in-sourcing or replacing previous partners, seeking technology and full-service capabilities.

• New partners are attracted by technology leadership and the ability to handle fast-growing therapeutic areas.

• Value proposition includes flexibility, innovation, and a compelling case for partnership.

Guidance, vaccine trials, and resource management

• Guidance range depends on the progress of two large vaccine trials; delays or cancellations would push results to the low end.

• Vaccine portfolio is mid-single digits of backlog, with COVID work in low single digits of revenue.

• 90-day trial delays impact first-half revenues and margins, but resources can be redeployed if trials resume.